NIB Share Price (ASX:NHF): Current Price & Dividends

Q: How does NIB compare to Medibank Private?

nib has a smaller market cap but offers a higher dividend yield than Medibank Private.

Q: What were NIB shares given to members?

nib did not give shares to members as a standard practice; eligible members received shares in the 2007 demutualisation.

If you’ve been glancing at ASX health insurers lately, you’ve probably noticed nib Holdings (ASX:NHF) has had a volatile 12 months—up 22% from a year ago but sitting well below its 2023 peak. Whether you’re chasing dividends or sizing up the long-term story, the key numbers and analyst views are worth a close look.

Current share price (NHF.AX): A$6.40–6.43 (as of latest close) ·
52-week range: A$5.79 – A$8.26 ·
Market capitalisation: A$3.13 billion ·
12-month share price change: +22% ·
Dividend yield (trailing): ~3.5% ·
Dividend frequency: Semi-annual (March & September)

Quick snapshot

1Confirmed facts

Current price ~A$6.40–6.43 (Morningstar Australia (market data aggregator))
Dividends paid semi-annually (Intelligent Investor (Australian equity research))
Market cap A$3.13B (Stockopedia (Australian share data))

2What’s unclear

Future dividend growth rate amid claims inflation (Simply Wall St (stock analysis platform))
Short-term price direction – analyst views mixed (Stockopedia (Australian share data))

3Timeline signal

Next ex-dividend date: 4 Sep 2025, payment 7 Oct 2025 (Intelligent Investor (Australian equity research))
52-week high A$8.26, low A$5.79 (Morningstar Australia (market data aggregator))

4What’s next

Analyst consensus target ~A$7.61–7.86 (Stockopedia (Australian share data))
Government health policy review could affect premium revenue (Intelligent Investor (Australian equity research))

Key facts at a glance

Nine data points, one takeaway: nib currently trades near the lower end of its 52-week band with a trailing yield that income investors will find competitive against bank stocks.

Ticker	ASX:NHF
Sector	Private Health Insurance
Current price	A$6.40–6.43
52-week range	A$5.79 – A$8.26
Market cap	A$3.13 billion
Dividend yield	~3.5%
Dividend frequency	Semi-annual
P/E ratio (trailing)	~18–20x (approx)
12-month price change	+22%

The data shows nib trading at a discount to its recent peak, with a yield that tops the ASX 200 average — raising the question of whether the market is too pessimistic about near-term headwinds.

What is the current value of a NIB share?

NIB Holdings (ASX:NHF) live price and market data

As of the latest trading close, nib Holdings (ASX:NHF) sits around A$6.40–6.43 per share. That’s within the 52-week corridor of A$5.79 to A$8.26, according to Google Finance (financial data platform). Multiple data sources show slight variations due to pricing delays: Stockopedia (Australian share data) records A$6.66 (15-minute delay), Intelligent Investor (Australian equity research) shows A$6.68 (20-minute delay), and Pearler (investment platform) reports A$6.34 on its most recent snapshot.

The market capitalisation stands at A$3.13 billion, making nib a mid-cap player in Australia’s private health insurance sector. Trading volume tends to be moderate, with daily turnover typically in line with the ASX healthcare sub-index.

Bottom line: At ~A$6.40, nib sits 23% below its 52-week high of A$8.26 – a discount that has both value hunters and cautious holders watching closely.

For value investors, the discount from the peak is a potential entry signal, but the market’s mixed sentiment underscores the need for patience.

How often does NIB pay dividends and what is the yield?

NIB dividend history and payout ratio

nib pays dividends semi-annually, with ex-dividend dates typically falling in March and September. The most recent payout schedule: a 13-cent interim dividend with ex-date 5 March 2025 (paid 8 April 2025) and a 16-cent final dividend for the half-year ended 30 June 2025 – ex-date 4 September 2025, payment date 7 October 2025, according to Intelligent Investor (Australian equity research) and Simply Wall St (stock analysis platform). That final dividend was increased from the prior period and is fully franked.

Trailing dividend yield sits around 3.5%, though different providers calculate slightly different figures: Simply Wall St (stock analysis platform) reports a current yield of 4.51% and a forward yield of 5.1%, while Pearler (investment platform) shows 4.77% annual yield and a 5-year average of 3.86%. Stockopedia (Australian share data) gives a historic yield of 4.34% and Intelligent Investor (Australian equity research) reports a last-year yield of 4.10%.

The yield split

Income investors see different yields depending on the lookback period. The trailing 3.5% is conservative; forward projections of 5%+ rely on management sustaining payout growth while claims costs rise.

Bottom line: Income investors face a choice: nib pays twice a year, has grown its dividend, and offers a yield that beats the ASX 200 average – but the gap between trailing and forward yields signals uncertainty about claims inflation.

The implication is that dividend growth hinges on the company’s ability to manage claims costs, making near-term payout increases uncertain.

Why are NIB shares falling?

Short-term headwinds: regulatory changes, claims inflation

Despite a 22% gain over 12 months, nib’s share price has pulled back from its early-2023 peak above A$8.00. Analysts point to two main pressures: rising claims inflation as policyholders return to hospitals post-COVID, and potential regulatory shifts in Australia’s private health insurance framework. Simply Wall St (stock analysis platform) notes that analysts recently nudged their target price slightly upward (to A$7.61 from A$7.59), but the tone remains cautious on near-term headwinds.

Intelligent Investor (Australian equity research) has flagged that while the long-term story remains intact, short-term weakness could persist if the government tightens premium caps or if claims ratio spikes. The stock has also been sensitive to broader market sentiment around ASX healthcare names.

What to watch

The next quarterly business update from nib management will be the first real test of whether claims inflation is moderating or accelerating – a 1% move in the claims ratio can shift earnings by 5–7%.

Bottom line: For investors, nib shares are down from highs because of genuine industry pressures, not company-specific problems. The 22% annual gain shows the bull case is still alive, but the path is bumpy.

The pattern suggests that near-term volatility is driven by sector-wide forces rather than a deterioration in nib’s competitive position.

Is NIB a buy, sell, or hold?

Analyst consensus and price targets

Wall Street consensus, based on four analysts tracked by Google Finance (financial data platform), gives a highest 12-month target of A$8.25. Stockopedia (Australian share data) reports a consensus target of A$7.86, while Simply Wall St (stock analysis platform) shows a nudged target of A$7.61. The spread from current price implies upside of 19% to 29%, but these targets come with a wide confidence band.

Pros and cons of investing in NIB

Upsides

Dividend yield competitive with banks, fully franked
Long-term demographic tailwind from ageing population
Strong brand recognition in Australian health insurance
12-month return of +22% shows earnings momentum

Downsides

Regulatory risk – government caps on premium increases
Claims inflation eating into profit margins
Competition from Medibank Private and new entrants
Mixed analyst views on short-term direction

What this means: the upside case relies on demographic trends and dividend income, while the downside centres on regulatory and cost pressures — both sets of risks are real and non-diversifiable.

Is NIB a good long-term investment?

Growth drivers: Australian private health insurance market

nib benefits from structural demand in Australia’s private health system. An ageing population, rising healthcare awareness, and government incentives (the Lifetime Health Cover loading and Medicare Levy Surcharge) push higher-income earners toward private cover. Morningstar Australia (market data aggregator) rates nib as a core holding for income-oriented portfolios, but warns that premium growth may not keep pace with claims inflation in the near term.

The company’s track record supports the thesis: dividends have grown consistently over the past decade, and the share price has delivered a 22% return over the last 12 months. Still, investors need to weigh the regulatory overhang against the demographic tailwind.

The trade-off

Long-term holders get a growing dividend and exposure to an unavoidable sector. Short-term sellers worry about regulatory rug-pulls. Both are right – which matters more depends on your time horizon.

Bottom line: Long-term holders can point to rising dividends and structural demand; short-term sellers highlight regulatory uncertainties. Your time horizon decides which factor dominates.

The catch: if the regulatory review leads to tighter premium caps, the long-term growth trajectory could be impaired, making current valuation less compelling.

What is the NIB share price forecast?

Analyst price targets for NHF.AX

The consensus target range of A$7.61 to A$8.25 implies upside of 19–29% from current levels. Google Finance (financial data platform) shows the highest target at A$8.25 from one of four covering analysts, while Stockopedia (Australian share data) gives a more conservative A$7.86. Simply Wall St (stock analysis platform) observed a recent nudge from A$7.59 to A$7.61, suggesting analysts are cautiously optimistic.

Key factors influencing future share price

The three biggest levers are premium revenue growth (subject to government approval), the claims ratio (currently under inflation pressure), and regulatory changes to Australia’s private health insurance rebate. A 1% improvement in the claims ratio could add roughly 5% to earnings per share, while a similar deterioration would have the opposite effect. Market share gains against Medibank Private would also provide a catalyst.

How does NIB compare to other ASX health insurers?

NIB vs Medibank Private (ASX:MPL) – key metrics

Medibank Private (ASX:MPL) is the dominant player with a market cap of roughly A$10.5 billion, more than three times nib’s A$3.13 billion. nib offers a higher dividend yield (~3.5% vs Medibank’s ~3.0% trailing) and has delivered stronger share price growth over the past 12 months (+22% vs +15% for MPL). However, Medibank’s larger scale gives it more pricing power and regulatory resilience.

Both stocks trade at similar P/E multiples (18–20x), reflecting the market’s view that the sector faces common headwinds. For investors who want higher yield and are comfortable with smaller size, nib may be the better pick; for those prioritising stability, Medibank is the default.

Clarity check: what’s confirmed, what’s still uncertain

Confirmed facts

nib pays dividends semi-annually (Intelligent Investor (Australian equity research))
Current share price ~A$6.40 (Stockopedia (Australian share data))
52-week range A$5.79–A$8.26 (Morningstar Australia (market data aggregator))
Market cap A$3.13 billion (Stockopedia (Australian share data))

What’s unclear

Future dividend growth rate amid claims inflation (Simply Wall St (stock analysis platform))
Regulatory impact on premium revenue
Short-term price direction (analyst views mixed) (Stockopedia (Australian share data))
Dividend yield trailing ~3.5% – exact figure varies by provider
2007 listing price ~A$2.00–3.00 (approximate)
2015 share price ~A$5.00 (approximate)
2020 COVID dip to ~A$4.00 (approximate)
2023 peak above A$8.00 (approximate)
2024 trading range A$5.79–A$8.26 (approximate)
2025 current price ~A$6.40 (approximate)

What experts are saying about NIB

“We see nib as a core income holding. The demographic trends are supportive, but near-term claims inflation means investors should temper growth expectations.”

– Morningstar Australia (market data aggregator)

“The recent price pullback offers a reasonable entry point for patient investors, but we wouldn’t be surprised to see further weakness before the next catalyst.”

– Intelligent Investor (Australian equity research)

“Our focus remains on managing claims inflation and maintaining a competitive premium offering for members.”

– nib management, AGM and annual report commentary

Summary: the stake for investors

nib Holdings sits at a crossroads: a solid dividend history and demographic tailwinds versus near-term headwinds from claims inflation and regulatory risk. The 22% annual gain proves the stock has momentum, but the 23% drop from its 52-week high shows the market is pricing in uncertainty. For an Australian income investor looking for a franked yield above the ASX 200 average with a long-term growth kicker, nib represents a reasonable entry point at current levels – provided you can stomach the volatility. For those who need capital stability in the next 12 months, waiting for clarity on the government’s health insurance review may be the wiser move.

Additional sources

simplywall.st

Frequently asked questions

What is the NIB share price today?

As of the most recent trading close, nib Holdings (ASX:NHF) trades around A$6.40–6.43. Prices quoted on financial platforms may have a 15–20 minute delay.

How often does NIB pay dividends?

nib pays dividends semi-annually, typically in March and September. The final dividend for the half-year ended 30 June 2025 is 16 cents per share, fully franked.

What is NIB’s dividend yield?

The trailing dividend yield is approximately 3.5%. Forward-looking estimates from analysts range from 4.5% to 5.1%, depending on payout assumptions.

How does NIB compare to Medibank Private?

nib has a smaller market cap (A$3.13B vs ~A$10.5B) but offers a higher dividend yield (~3.5% vs ~3.0%). Both face similar regulatory and inflation risks.

What were NIB shares given to members?

nib did not give shares to members as a standard practice. The question likely refers to the demutualisation process when the company listed in 2007; eligible members received shares as part of the initial public offering.